Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Business Wire

2024-11-13

LONDON, November 13, 2024--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20^th at 2:00 p.m. GMT.

The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113003941/en/

Contacts

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2483007565"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483007565\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483007565?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GD9Y436q17boIFTJmvRpNQ--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e383415f665942a1dcb64a8dff473096","is_english":true,"pubTime":"2024-11-13 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483007565","market":"us","top_or_hot":-1,"title":"Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"652\" src=\"https://s.yimg.com/uu/api/res/1.2/y96Dt2gC8C6vs09KiOOyeg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/e383415f665942a1dcb64a8dff473096\" title=\"\" width=\"1756\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>LONDON, November 13, 2024</b>--(BUSINESS WIRE)--Silence <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plc, Nasdaq: SLN (\"Silence\" or the \"Company\"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20<sup>th</sup> at 2:00 p.m. GMT.</p>\n<p>The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.</p>\n<p><b>About Silence Therapeutics</b></p>\n<p>Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241113003941/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Silence Therapeutics plc </b><br/>Gem Hopkins, <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Head of IR and Corporate Communications<br/>ir@silence-therapeutics.com <br/>Tel: +1 (646) 637-3208<br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/silence-therapeutics-participate-fireside-chat-130000492.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LONDON, November 13, 2024--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (\"Silence\" or the \"Company\"), a global clinical stage biotechnology company committed to transforming people’s lives ...</p>\n\n<a href=\"https://finance.yahoo.com/news/silence-therapeutics-participate-fireside-chat-130000492.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"医疗保健服务","start_time":0,"source_url":"https://finance.yahoo.com/news/silence-therapeutics-participate-fireside-chat-130000492.html","article_id":"2483007565","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GD9Y436q17boIFTJmvRpNQ--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e383415f665942a1dcb64a8dff473096"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483007565","pubTimestamp":1731502800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"LONDON, November 13, 2024----Silence Therapeutics plc, Nasdaq: SLN , a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT.The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communicationsir@silence-therapeutics.com Tel: +1  637-3208","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"医疗保健服务","BK4139":"生物科技","BK4137":"综合支持服务","SLN":"Silence Therapeutics Plc","LENZ":"Therapeutics"},"translate_title":"Silence Therapeutics将参加杰富瑞伦敦医疗保健会议的炉边谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"LENZ":1,"SLN":0.9},"content_text":"LONDON, November 13, 2024--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (\"Silence\" or the \"Company\"), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT.\nThe live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.\nAbout Silence Therapeutics\nSilence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241113003941/en/\nContacts\nSilence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communicationsir@silence-therapeutics.com Tel: +1 (646) 637-3208","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}